{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:13:34Z","timestamp":1793873614954,"version":"4.6.1"},"reference-count":79,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,5,12]],"date-time":"2005-05-12T00:00:00Z","timestamp":1115856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurogastroenterology Motil"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:p><jats:bold>Abstract\u2002<\/jats:bold>Recent research has provided new information about drugs that could be used to treat functional motility disorders. Promotility drugs accelerate gastric emptying or colonic transit and these properties may contribute to their efficacy in treating symptoms associated with gastroparesis, functional dyspepsia or constipation. 5\u2010Hydroxytryptamine4 receptors are targets for drugs (tegaserod, renzapride) that treat symptoms in constipated irritable bowel syndrome patients and in gastroparesis. Drugs acting at motilin (erythromycin) and cholecystokinin\u20101 (dexloxiglumide) receptors accelerate gastric emptying. Dexloxiglumide might be useful in the treatment of functional dyspepsia particularly that associated with lipid intake. Alvimopan is a<jats:italic>\u03bc<\/jats:italic>\u2010opioid receptor antagonist that does not cross the blood brain barrier. Alvimopan is effective in treating postsurgical ileus and perhaps opiate\u2010induced bowel dysfunction. Successes and failures of recent efforts to develop promotility agents revealed opportunities and challenges for developing new promotility drugs. The pharmacological properties of partial agonists might be exploited to develop effective promotility drugs. However, opposing actions of promotility agents on motility (increased contraction<jats:italic>vs<\/jats:italic>decreased accommodation) limit the clinical efficacy of drugs with these opposing actions. Selection of appropriate patient populations for evaluation of new drugs is also critical.<\/jats:p>","DOI":"10.1111\/j.1365-2982.2005.00675.x","type":"journal-article","created":{"date-parts":[[2005,9,26]],"date-time":"2005-09-26T15:36:03Z","timestamp":1127748963000},"page":"643-653","source":"Crossref","is-referenced-by-count":109,"title":["Basic and clinical pharmacology of new motility promoting agents"],"prefix":"10.1111","volume":"17","author":[{"given":"J. J.","family":"Galligan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,5,12]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02180.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.013"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.028"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00167041"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1998.70062252.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb10172.x"},{"key":"e_1_2_8_8_2","first-page":"631","article-title":"Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility","volume":"47","author":"Briejer MR","year":"1995","journal-title":"Pharmacol Rev"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703615"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00169544"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00168686"},{"key":"e_1_2_8_12_2","doi-asserted-by":"crossref","unstructured":"KilbingerH GebquerA HaasJ LedinskyH RizziCA.Benzimidazolenes and tenzapride facilitate qcetylcholive release from guinea pig myenteric plekusvia 5\u2010HT4receptors Naunyn Schmiedbeng's Arch Pharmacol.1995;351:229\u201336.","DOI":"10.1007\/BF00233241"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2004.00505.x"},{"key":"e_1_2_8_14_2","first-page":"G778","article-title":"5\u2010HT released by mucosal stimuli initiates peristalsis by activating 5\u2010HT4\/5\u2010HT1P receptors on sensory CGRP neurons","volume":"270","author":"Grider JR","year":"1996","journal-title":"Am J Physiol"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2003.00428.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00013a010"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705929"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70203-3"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.053256"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702665"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb14006.x"},{"key":"e_1_2_8_22_2","first-page":"1270","article-title":"SDZ HTF 919 stimulates canine colonic motility and transit in vivo","volume":"280","author":"Nguyen A","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_23_2","first-page":"CD003960","article-title":"Tegaserod for the treatment of irritable bowel syndrome","volume":"1","author":"Evans BW","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01103.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01775.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-004-0018-0"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1987.tb08985.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb12211.x"},{"key":"e_1_2_8_29_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-3565(24)29223-5","article-title":"Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether\u2010a\u2010gogo K(+) channel","volume":"299","author":"Potet F","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1990.tb14113.x"},{"key":"e_1_2_8_31_2","first-page":"G230","article-title":"5\u2010HT1A and 5\u2010HT4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neurons","volume":"266","author":"Pan H","year":"1994","journal-title":"Am J Physiol"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00233241"},{"key":"e_1_2_8_33_2","first-page":"1312","article-title":"Effect of cisapride and renzapride on gastrointestinal motility and plasma motilin concentration in dogs","volume":"281","author":"Song CW","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00391-X"},{"key":"e_1_2_8_35_2","first-page":"A640","article-title":"Efficacy and safety of renzapride in patients with constipation\u2010predominant IBS: A Phase IIb study in the UK Primary Healthcare Setting","volume":"126","author":"Meyers NL","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_8_36_2","first-page":"A644","article-title":"A Phase IIb clinical study of renzapride in mixed\u2010symptom (alternating) irritable bowel syndrome","volume":"126","author":"Henderson JC","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1991.tb00014.x"},{"key":"e_1_2_8_38_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0016-5085(93)91089-Z","article-title":"Erythromycin and other macrolides as prokinetic agents","volume":"105","author":"Peeters TL","year":"1993","journal-title":"Gastroenterology"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(96)00333-6"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5423.2184"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(94)00111-A"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00305.2004"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91097-N"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07167.x"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.3.395"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00868.x"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.2.203"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.4.612"},{"key":"e_1_2_8_49_2","first-page":"317","article-title":"What comes after macrolides and other motilin stimulants","volume":"49","author":"Tack J","year":"2001","journal-title":"Gut"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34230"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200207000-00005"},{"key":"e_1_2_8_52_2","first-page":"G448","article-title":"Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans","volume":"271","author":"Borovicka J","year":"1996","journal-title":"Am J Physiol"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70227-1"},{"key":"e_1_2_8_54_2","first-page":"G184","article-title":"Distinct receptors for cholecystokinin and gastrin on muscle cells of stomach and gallbladder","volume":"259","author":"Grider JR","year":"1990","journal-title":"Am J Physiol"},{"key":"e_1_2_8_55_2","first-page":"G165","article-title":"Reflex decreases in intragastric pressure in response to cholecystokinin in rats","volume":"253","author":"Raybould HE","year":"1987","journal-title":"Am J Physiol"},{"key":"e_1_2_8_56_2","first-page":"G625","article-title":"Intestinal lipid inhibits gastric emptying via CCK and a vagal capsaicin\u2010sensitive afferent pathway in rats","volume":"267","author":"H\u00f6lzer P","year":"1994","journal-title":"Am J Physiol"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.1999.276.3.G767"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018868601475"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03804.x"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705769"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-0115(01)00383-4"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.4.500"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8613041"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0953-0673.1996.00411.x"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00308.2003"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00351.2003"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.3.347"},{"issue":"96","key":"e_1_2_8_68_2","first-page":"S31","article-title":"The CCK\u20101 receptor antagonist dexloxiglumide","volume":"96","author":"D'Amato M","year":"2001","journal-title":"Am J Gastroenterology"},{"key":"e_1_2_8_69_2","unstructured":"http:\/\/www.biospace.com\/ccis\/news_story.cfm?StoryID=13939520&full=1"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-3150.2004.00554.x"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(87)90018-9"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363070-00003"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-3150.2004.00559.x"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00041a003"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.112680"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010564"},{"key":"e_1_2_8_77_2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/01.sla.0000141158.27977.66","article-title":"Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double\u2010blind, placebo\u2010controlled, phase III trial of major abdominal surgery and postoperative ileus","volume":"240","author":"Wolff BG","year":"2004","journal-title":"Ann Surg"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-002-0588-0"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(99)01351-6"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.73.011303.073940"}],"container-title":["Neurogastroenterology &amp; Motility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2982.2005.00675.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2982.2005.00675.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T15:21:59Z","timestamp":1736004119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2982.2005.00675.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,12]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1365-2982.2005.00675.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2982.2005.00675.x","archive":["Portico"],"relation":{},"ISSN":["1350-1925","1365-2982"],"issn-type":[{"value":"1350-1925","type":"print"},{"value":"1365-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,12]]}}}